As of Wednesday close, Fate Therapeutics Inc.’s (NASDAQ:FATE) stock was down -$0.07, moving down -2.58 percent to $2.64. The average number of shares traded per day over the past five days has been 1,680,180 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.07 fall in that time frame. In the last twenty days, the average volume was 1,998,350, while in the previous 50 days, it was 1,863,212.
Since last month, FATE stock retreated -33.50%. Shares of the company fell to $2.49 on 08/25/23, the lowest level in the past month. A 52-week high of $29.42 was reached on 01/05/23 after having rallying from a 52-week low of $2.49. Since the beginning of this year, FATE’s stock price has dropped by -73.84% or -$7.45, and marked a new high 3 times. However, the stock has declined by -91.03% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
FATE stock investors should be aware that Fate Therapeutics Inc. (FATE) stock had its last reported insider trading activity 13 days ago on Aug 18. Dulac Edward J III, the Chief Financial Officer of the company, disposed of 4,718 shares for $2.80 on Aug 18. It resulted in a $13,210 divestment by the insider. Xu Yuan sold 632 shares at an average price of $3.71 on Aug 04. The insider now owns 9,302 shares following the transaction. On Jul 05, Chief Financial Officer Dulac Edward J III sold 5,182 shares at $4.83 apiece. The transaction was valued at $25,029.
Valuation Metrics
The stock’s beta is 1.46. Besides these, the trailing price-to-sales (P/S) ratio of 2.12, the price-to-book (PB) ratio of 0.59.
Financial Health
In the three months ended June 29, Fate Therapeutics Inc.’s quick ratio stood at 8.80, while its current ratio was 8.80, showing that the company is able to pay off its debt. Based on annual data, FATE earned $404.69 million in gross profit and brought in $96.3 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -63.70%. Return on equity (ROE) for the past 12 months was -44.10%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. FATE’s revenue fell -1894.62% to $58.98 million during the quarter, while net income inched up to $0.93 million. While analysts expected Fate Therapeutics Inc. to report -$0.59 quarterly earnings, the actual figure was -$0.54 per share, beating the consensus estimate by 8.50%. During the quarter, the company generated -$61.04 million in EBITDA. The liabilities of Fate Therapeutics Inc. were 147.0 million at the end of its most recent quarter ended June 29, and its total debt was $106.35 million. The value of shareholders’ equity is $98.56 million.
Technical Picture
This quick technical analysis looks at Fate Therapeutics Inc.’s (FATE) price momentum. With a historical volatility rate of 14.09%, the RSI 9-day stood at 24.81% on 30 August.
With respect to its five-day moving average, the current Fate Therapeutics Inc. price is down by -2.58% percent or -$0.07. At present, FATE shares trade -29.79% below its 20-day simple moving average and -54.87% percent below its 100-day simple moving average. However, the stock is currently trading approximately -55.03% below its SMA50 and -87.41% below its SMA200.
Stochastic coefficient K was 17.82% and Stochastic coefficient D was 14.60%, while ATR was 0.17. Given the Stochastic reading of 18.01% for the 14-day period, the RSI (14) reading has been calculated as 23.15%. As of today, the MACD Oscillator reading stands at -0.01, while the 14-day reading stands at -0.09.
Analyst Ratings
Fate Therapeutics Inc. (FATE) has been rated Hold by analysts. According to 1 brokerage firm, FATE is a sell, and 14 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 1 analyst rate Fate Therapeutics Inc. stock as buy, with 5 recommending it as overweight.
With a median target price of $6.00, the current consensus forecast for the stock is $4.00 – $16.00. Based on these forecasts, analysts predict Fate Therapeutics Inc. (FATE) will achieve an average price target of $7.19.
